Brief: Reviva Pharmaceuticals Announces Positive Safety Data From Drug-Drug Interaction Clinical Study Of Brilaroxazine
15/12/2022 11:02
Dec 15 (Reuters) - Reviva Pharmaceuticals Holdings, Inc.
RVPH.O :
* REVIVA PHARMACEUTICALS ANNOUNCES POSITIVE SAFETY DATA FROM
DRUG-DRUG INTERACTION CLINICAL STUDY OF BRILAROXAZINE
* REVIVA PHARMACEUTICALS HOLDINGS, INC. - TOPLINE DATA FOR
PIVOTAL
PHASE 3 RECOVER TRIAL EVALUATING BRILAROXAZINE FOR SCHIZOPHRENIA
EXPECTED IN MID-2023
Source text for Eikon: ID:nGNXtR9Rc
Further company coverage: RVPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reviva Pharmaceuticals Holdings
See all newsReviva Pharmaceuticals Q1 net loss narrows on lower expenses
Brief: Reviva Pharmaceuticals Holdings Inc - To Be Delisted From Nasdaq Trading Suspended As Of May 14, 2026 - SEC Filing
Brief: Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights
Reviva Pharmaceuticals' 2025 net loss narrows on lower R&D spending
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture